Company patents
AVIDITY BIOSCIENCES, INC.
AVIDITY BIOSCIENCES, INC. demonstrates a highly concentrated patent strategy, with Pharmaceutical Preparations, Peptides & Proteins, and Therapeutic Activity (Pharma) collectively accounting for over 90% of its 73-patent portfolio. While these core areas showed significant growth in 2024 and 2025, with Pharmaceutical Preparations growing by 50.0% in 2025 and Peptides & Proteins by 80.0% in 2024, the sharp year-over-year declines observed so far in 2026 across all categories, including a 100.0% drop in Acyclic / Cyclic Compounds (Other Elements), suggest a potential shift in filing pace or focus, though 2026 data is partial.
Patent Trend by Technology Area
Yearly patent publications since 2023
Product themes
Product-level themes inferred from filings since 2023, with category chips showing where each theme appears. Select a theme to filter the patents below.
73 US filings (since 2023) · 4 categories · 5 themes
Therapeutic strategies employing nucleic acids (DNA, RNA, oligonucleotides) to modulate gene expression, deliver genetic material, or interfere with disease-causing pathways. Includes gene therapy using viral vectors.
Design and synthesis of acyclic or carbocyclic organic compounds that selectively modulate specific biological targets or pathways for the treatment of diseases.
Design and modification of antibodies or antibody-derived fragments for targeted therapeutic intervention, including bispecific formats, Fc region modifications, and activatable constructs.
Development of lipid-based nanoparticles, liposomes, or other molecular platforms to encapsulate and deliver therapeutic agents, particularly nucleic acids, to target tissues or improve pharmacokinetics.
Development of therapeutic approaches involving the genetic modification of cells (e.g., T cells, stem cells, macrophages) or the use of viral/non-viral vectors to deliver genetic material for disease treatment.
Patents
Showing 1-10 of 106